Developer docs
API playgroundTry for free, no card

Search company profiles

OBiO Technology

Full company profile

uuid0002u5d

Namestring
OBiO Technology
Websiteurl
obiosh.com
Company typeenum
Private
Founded yearint
2013
Short descriptiontext

OBiO Technology is a Shanghai-based, privately held provider of viral-based gene therapy CRO and CDMO/CMO services, founded in 2013 to serve biotech and pharmaceutical sponsors developing gene therapies through research, process development, and GMP manufacturing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
viral vector CDMO, gene therapy CRO, viral vector manufacturing, gene therapy services, biologics contract manufacturing
Industry4 codes
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLAAACAM
Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Gene Therapy CDMO Services
Cost components4 values
Personnel, Operations, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

OBiO Technology provides outsourced contract research (CRO) and contract development and manufacturing (CDMO/CMO) services focused on viral vector-based gene therapy. Offerings cover preclinical research support, viral vector process development, and GMP-grade manufacturing for gene therapy developers. The company delivers these as integrated service engagements rather than off-the-shelf products.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Viral-Based Gene Therapy CRO Services
CategoryContract Research Services (CRO)
No data
Peers10 records
TypeDirect peer
Description

Largest China-based gene therapy CDMO offering viral vector manufacturing and integrated development services. Direct competitor for OBiO across both domestic Chinese gene therapy developers and global clients seeking China-based manufacturing.

TypeDirect peer
Description

CDMO arm of GenScript offering viral vector, cell therapy, and plasmid manufacturing with global reach. Competes head-to-head with OBiO for gene therapy CRO/CDMO contracts from Chinese and Asia-Pacific sponsors.

TypeBroad incumbent
Description

Global CDMO with dedicated gene therapy/viral vector manufacturing capacity across multiple sites. Competes with OBiO for international gene therapy sponsors seeking commercial-scale viral vector supply.

TypeBroad incumbent
Description

Large global CDMO with significant viral vector and gene therapy manufacturing capabilities acquired via Paragon. Represents the scaled incumbent alternative OBiO must differentiate against for late-stage contracts.

TypeBroad incumbent
Description

Global CDMO leader with expanding cell and gene therapy services including viral vector manufacturing. Sets the competitive benchmark for scale, quality systems, and breadth that OBiO must match.

6Yposkesi
TypeDirect peer
Description

Europe-based CDMO specialized in AAV and lentiviral vector manufacturing for gene therapy. Comparable service offering to OBiO with similar focus on viral vector production for clinical-stage gene therapy developers.

TypeDirect peer
Description

Specialized manufacturer of plasmids, mRNA, and proteins used in gene therapy production. Provides upstream raw materials into the gene therapy value chain that overlaps with OBiO's CDMO customer base.

TypeBroad incumbent
Description

Global bioservices CDMO offering viral vector manufacturing, biosafety testing, and cell banking for gene therapy. Competes with OBiO for both manufacturing slots and ancillary testing services.

9Cobra Biologics (Charles River Laboratories)
TypeBroad incumbent
Description

CDMO providing viral vector and plasmid DNA manufacturing for gene therapy and viral vaccine clients. Direct alternative for sponsors comparing OBiO against established European CDMOs.

TypeBroad incumbent
Description

Diversified life sciences giant offering viral vector development and manufacturing through its CDMO services. Sets the high-water mark for integrated CRO-to-CDMO scale against which OBiO competes.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OBiO Technology

Gene Therapy CDMO Servicesobiosh.com

OBiO Technology is a Shanghai-based, privately held provider of viral-based gene therapy CRO and CDMO/CMO services, founded in 2013 to serve biotech and pharmaceutical sponsors developing gene therapies through research, process development, and GMP manufacturing.

OBiO Technology firmographics

Firmographics
Name
OBiO Technology
Website
https://obiosh.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
501–1,000 employees
Short description
OBiO Technology is a Shanghai-based, privately held provider of viral-based gene therapy CRO and CDMO/CMO services, founded in 2013 to serve biotech and pharmaceutical sponsors developing gene therapies through research, process development, and GMP manufacturing.
Ownership category
akta.pro rank

OBiO Technology industry classification

Industry
Product category
Gene Therapy CDMO Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLAAACAM
Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Viral vector CDMO
  • Gene therapy CRO
  • Viral vector manufacturing
  • Gene therapy services
  • Biologics contract manufacturing

Where OBiO Technology is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Markets served

OBiO Technology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure

OBiO Technology product offering

Product offering

Core offering

OBiO Technology provides outsourced contract research (CRO) and contract development and manufacturing (CDMO/CMO) services focused on viral vector-based gene therapy. Offerings cover preclinical research support, viral vector process development, and GMP-grade manufacturing for gene therapy developers. The company delivers these as integrated service engagements rather than off-the-shelf products.

Differentiator

Problem solved

Functional benefit

Products and services

  • Viral-Based Gene Therapy CRO Services

Companies that use OBiO Technology

Customer profile

Ideal customer profiles1 record

OBiO Technology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

OBiO Technology competitors and assessment

Company assessment

Direct peers

  • WuXi Advanced Therapies Unit (WuXi AppTec): Largest China-based gene therapy CDMO offering viral vector manufacturing and integrated development services. Direct competitor for OBiO across both domestic Chinese gene therapy developers and global clients seeking China-based manufacturing.
  • GenScript ProBio: CDMO arm of GenScript offering viral vector, cell therapy, and plasmid manufacturing with global reach. Competes head-to-head with OBiO for gene therapy CRO/CDMO contracts from Chinese and Asia-Pacific sponsors.
  • Yposkesi: Europe-based CDMO specialized in AAV and lentiviral vector manufacturing for gene therapy. Comparable service offering to OBiO with similar focus on viral vector production for clinical-stage gene therapy developers.
  • Aldevron: Specialized manufacturer of plasmids, mRNA, and proteins used in gene therapy production. Provides upstream raw materials into the gene therapy value chain that overlaps with OBiO's CDMO customer base.

Broad incumbents

  • AGC Biologics: Global CDMO with dedicated gene therapy/viral vector manufacturing capacity across multiple sites. Competes with OBiO for international gene therapy sponsors seeking commercial-scale viral vector supply.
  • Catalent (Paragon Gene Therapy): Large global CDMO with significant viral vector and gene therapy manufacturing capabilities acquired via Paragon. Represents the scaled incumbent alternative OBiO must differentiate against for late-stage contracts.
  • Lonza: Global CDMO leader with expanding cell and gene therapy services including viral vector manufacturing. Sets the competitive benchmark for scale, quality systems, and breadth that OBiO must match.
  • Bioreliance (MilliporeSigma / Merck KGaA BioReliance): Global bioservices CDMO offering viral vector manufacturing, biosafety testing, and cell banking for gene therapy. Competes with OBiO for both manufacturing slots and ancillary testing services.
  • Cobra Biologics (Charles River Laboratories): CDMO providing viral vector and plasmid DNA manufacturing for gene therapy and viral vaccine clients. Direct alternative for sponsors comparing OBiO against established European CDMOs.
  • Thermo Fisher Scientific (Patheon Viral Vector Services): Diversified life sciences giant offering viral vector development and manufacturing through its CDMO services. Sets the high-water mark for integrated CRO-to-CDMO scale against which OBiO competes.

Market position

Customer concentration

OBiO Technology social profiles

Digital presence

OBiO Technology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OBiO Technology leadership team

Management profile

Number of profiles

Profiles2 records

OBiO Technology funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OBiO Technology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OBiO Technology

What does OBiO Technology do?

OBiO Technology provides outsourced contract research (CRO) and contract development and manufacturing (CDMO/CMO) services focused on viral vector-based gene therapy. Offerings cover preclinical research support, viral vector process development, and GMP-grade manufacturing for gene therapy developers. The company delivers these as integrated service engagements rather than off-the-shelf products.

When was OBiO Technology founded?

OBiO Technology was founded in 2013. It employs 501 to 1,000 people.

Where is OBiO Technology based?

OBiO Technology is headquartered in Shanghai, China, in the Asia region.

Who are OBiO Technology's main competitors?

Direct peers on record are WuXi Advanced Therapies Unit (WuXi AppTec), GenScript ProBio, Yposkesi and Aldevron. Broad incumbents are AGC Biologics, Catalent (Paragon Gene Therapy), Lonza, Bioreliance (MilliporeSigma / Merck KGaA BioReliance), Cobra Biologics (Charles River Laboratories) and Thermo Fisher Scientific (Patheon Viral Vector Services).

Does OBiO Technology have an API?

No public API is recorded for OBiO Technology.

What industry is OBiO Technology in?

OBiO Technology's product category is Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOBiO Technology Officially Launched the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic DiseasesOBiO Technology, a contract development and manufacturing organization for cell and gene therapy, officially launched the "Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases" on May 23, 2024, at a rare disease research conference in Shanghai. The center was jointly initiated by OBiO Technology, Shanghai Children's Medical Center, and Zhejiang Hope for Rare Foundation, aiming to advance clinical research and therapeutic innovation in pediatric rare and genetic diseases through an open cooperation platform for enterprises, universities, and research institutes. The platform seeks to leverage regional policy advantages to enhance the technological and industrial competitiveness of cell and gene therapy through industry-academia-research collaboration.PR NewswireOBiO Technology will showcase at American Society of Gene & Cell TherapyOBiO Technology (Shanghai) Corp., Ltd. announced it will participate in the American Society of Gene & Cell Therapy conference in Maryland, USA from May 7th to 11th, 2024. The company will present nine posters showcasing self-developed patented achievements, process optimization breakthroughs, and cutting-edge technology introductions in the gene and cell therapy space. The presentations highlight OBiO's advances in viral vector yield, production efficiency, and cost reduction for gene therapy manufacturing.PR NewswireOBiO annonce un partenariat stratégique avec Refreshgene pour la commercialisation d'un produit de thérapie géniqueOBiO Technology (Shanghai) Corp. Ltd. has signed a strategic partnership agreement with Refreshgene Therapeutics to provide CDMO/CMO services for Refreshgene's RRG-001 gene therapy pipeline, covering process development, large-scale cGMP commercial manufacturing, and global commercial development. OBiO will leverage its 15 vector production lines and 20 cell production lines to support the clinical and commercial launch of RRG-001, a gene therapy product targeting congenital deafness using the world's first AAV dual-vector system in clinical trials. The CEOs of both companies described the collaboration as a major milestone aimed at accelerating the product's path to market and addressing unmet medical needs for patients.PR NewswireOBiO gibt strategische Partnerschaft mit Refreshgene zur Kommerzialisierung eines Gentherapieprodukts bekanntOBiO Technology (Shanghai) Corp., Ltd. (688238.SH) announced a strategic partnership with Refreshgene Therapeutics, under which OBiO will provide CDMO/CMO services for Refreshgene's RRG-001 gene therapy pipeline, including process development, commercial cGMP manufacturing, and global business development. Refreshgene is a gene therapy company focused on AAV-based treatments for retinal diseases and congenital deafness, including the world's first dual AAV vector technology to enter clinical trials for congenital deafness. The collaboration aims to advance the clinical application and market launch of the RRG-001 therapy product.PR NewswireOBiO anuncia una alianza estratégica con Refreshgene para comercializar un producto de terapia génicaOBiO Technology (Shanghai) Corp., Ltd. has announced a strategic agreement with Refreshgene Therapeutics to provide CDMO/CMO services for Refreshgene's gene therapy product line RRG-001, which targets retina diseases and congenital deafness. Under the agreement, OBiO will leverage its cGMP large-scale manufacturing capabilities and global business development expertise to support the clinical and commercial development of RRG-001. The partnership aims to advance advanced therapies for patients worldwide, with OBiO providing comprehensive CRO/CDMO services from preclinical research through large-scale commercial manufacturing.PR NewswireOBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy ProductOBiO Technology (Shanghai) Corp., Ltd. announced a strategic partnership with Refreshgene Therapeutics to provide CDMO/CMO services for Refreshgene's RRG-001 gene therapy pipeline. OBiO will leverage its capabilities in process development, large-scale cGMP commercial production, and global business development to support the clinical application and commercialization of the gene therapy product. Refreshgene, the first gene therapy company globally to apply dual AAV vector technology in congenital deafness clinical trials, will collaborate with OBiO to advance its retinal disease and congenital deafness therapies.ContractpharmaOBiO Technology Adds Univercells Upstream Platform for Gene Therapy Mfg.OBiO Technology and Univercells Technologies signed a strategic agreement to deploy the NevoLine Upstream platform with scale-X bioreactors in OBiO's GMP Shanghai facility. The collaboration combines OBiO's process development scientists with Univercells' biomanufacturing technology to accelerate gene therapy manufacturing. The companies plan to scale up the oncolytic HSV-1 process and expand to other modalities.PR NewswireOBiO and CHINAGENE reached a strategic agreement of commercial manufacturing services for gene therapy productsOn April 21, 2023, OBiO Technology (Shanghai) Corp., Ltd. (OBiO) announced a strategic agreement with CHINAGENE for commercial manufacturing collaboration of gene therapy products, with OBiO providing comprehensive contract development and manufacturing services including large-scale cGMP manufacturing, process characterization, validation, formulation, filling, and commercial manufacturing for CHINAGENE's ophthalmic gene therapy products. The partnership builds on prior cooperation where OBiO helped CHINAGENE obtain IND approvals from both China's NMPA and the U.S. FDA for their lead product ZVS101e, targeting Bietti crystalline dystrophy and crystallization-like retinitis pigmentosa.PR NewswireFDA Accepts GMP Plasmid DMF of OBiO TechnologyOBiO Technology (Shanghai) Corp., Ltd., a gene and cell therapy-focused CRO and CDMO, announced that the FDA has accepted its GMP plasmid DNA drug master file (DMF Number 037766), enabling direct reference for IND filings for lentiviral vectors, cell therapies, and stem cell products. The acceptance streamlines the regulatory review process and reduces time and communication costs for clients filing IND applications. In 2022, OBiO supported clients in obtaining 12 IND clearances including 3 FDA IND approvals, and the company is constructing a 77,000 m2 GMP production base in Shanghai's Lingang Special Area.PR NewswireOBiO Technology to Present Data on OVersatile™ Platform for Process Development of Herpes Simplex Virus and Vaccinia Virus Products at the 25th ASGCT Annual MeetingOBiO Technology announced it will present research on its OVersatile™ platform at the American Society of Gene & Cell Therapy 25th Annual Meeting in Washington, D.C. on May 16-19, 2022, showcasing novel manufacturing technologies for herpes simplex virus and vaccinia virus-based vector production. The platform enables scalable, high-titer process development and manufacturing solutions for gene and cell therapy products. This represents a scientific conference presentation announcement highlighting the company's R&D capabilities in viral vector manufacturing.